You are using an outdated browser. Please upgrade your browser to improve your experience.

capmatinib

Ligand Summary
Ligand Structure
Rendered image for the query structure
Description
Capmatinib is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.
Synonyms & Links
Guide to Pharmacology: 7904
DrugCentral: 5392
LyCHI:  KLGQTGH34Q2A


loading...
Target Activities